Biocytogen attended AACR Annual Meeting 2023, held from April 14-19 in Orlando, Florida! We presented the latest advances in our therapeutic antibody assets and platforms, animal models and service offerings at our Booth 723 and our 25 posters!

Download Our Posters

Our posters comprise:

RenMab^TM-Based Fully Human Antibody Discovery Platforms

RenNano^TM Mice: A Heavy-Chain-Only Antibody Platform for the Generation of Nanobody Therapeutics

Poster Number: LB210

Session: Late-Breaking Research: Immunology 2

Date/Time: April 18, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/9730

Discovery of RenNano^TM-Derived Human Heavy-Chain-Only Antibodies That Cross the Blood-Brain-Barrier

Poster Number: LB211

Session: Late-Breaking Research: Immunology 2

Date/Time: April 18, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/9731

Targeting Intracellular Tumor Antigens Using Fully Human TCR Mimic Antibodies Derived from HLA Transgenic RenMice^TM

Poster Number: 2752

Session: Innovative Assay Technologies

Date/Time: April 17, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/2509

The RenMice^TM HiTS (Hyperimmune Target Specific) Platform Facilitates Identification of Novel Therapeutic Antibodies for Challenging Targets

Poster Number: 5320

Session: High-throughput Screening, Lead Identification and Optimization, and in Silico Drug Discovery

Date/Time: April 18, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/5254

Fully Human Monoclonal Antibody Assets

1C3, A Novel Non-Blocking Anti-Human TNFR2 Antibody, Promotes Effector T Cell Responses and Demonstrates Potent Anti-Tumor Activity

Poster Number: 6436

Session: Immunotherapy Strategies and Mechanisms

Date/Time: April 19, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6990

*Novel Preclinical Candidates Targeting B7-H3, 6B5 and 10F7, Are Suitable for Development into Various Drug Modalities

Poster Number: 1528

Session: Antibody Drug Conjugates

Date/Time: April 17, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/2650

BCG008, A Human Siglec-15 Blocking Antibody, Displays Potent Anti-Tumor Activity in Siglec-15-Humanized Mice

Poster Number: 6435

Session: Immunotherapy Strategies and Mechanisms

Date/Time: April 19, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6976

D02, A Novel, Non-Blocking Antibody Targeting IL2RA, Exhibits Significant Anti-Tumor Activity in IL2RA-Humanized Mice

Poster Number: 1866

Session: Therapeutic Antibodies 1

Date/Time: April 17, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3781

RenLite^®-derived Fully Human Bispecific ADC Assets

A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy

Poster Number: 2977

Session: Therapeutic Antibodies 3

Date/Time: April 17, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3674

YH013, a Novel EGFR x MET Bispecific Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy

Poster Number: 2978

Session: Therapeutic Antibodies 3

Date/Time: April 17, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3670

A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity

Poster Number: 6325

Session: Anticancer Immunotherapeutics

Date/Time: April 19, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/4039

BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET

Poster Number: LB212

Session: Late-Breaking Research: Immunology 2

Date/Time: April 18, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/9732

Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer

Poster Number: LB216

Session: Late-Breaking Research: Immunology 2

Date/Time: April 18, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/9736

A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy

Poster Number: LB215

Session: Late-Breaking Research: Immunology 2

Date/Time: April 18, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/9735

A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1

Poster Number: LB214

Session: Late-Breaking Research: Immunology 2

Date/Time: April 18, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/9734

Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate

Poster Number: LB213

Session: Late-Breaking Research: Immunology 2

Date/Time: April 18, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/9733

Off-the-Shelf Mouse Models - Humanized Mice

A Novel Triple Humanized B-hPD-1/hPD-L1/hCCR8 Mouse Model to Evaluate In vivo Efficacy of Combination Therapies

Poster Number: 3233

Session: Combination Immunotherapies 1

Date/Time: April 17, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3126

B-hCD94/hNKG2A Mice Provide a Preclinical Tool for Evaluating Therapeutic Antibodies Targeting Human NKG2A

Poster Number: 3286

Session: Combination Immunotherapies 2

Date/Time: April 17, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/4750

Generation of Humanized TREM2 Mice for Preclinical Evaluation of Therapeutics Targeting Tumor-Associated Macrophages

Poster Number: 5209

Session: Novel Preclinical Models for Cancer Immunotherapy

Date/Time: April 18, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6988

Humanized OX40/OX40L Mice as a Tool for Evaluating Novel Therapeutics

Poster Number: 5178

Session: Modifiers of the Tumor Microenvironment

Date/Time: April 18, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/3613

In vivo Efficacy Evaluation of Anti-Human VEGFR2 Antibodies in Humanized B-hVEGFR2 Mice

Poster Number: 4592

Session: Advances in Angiogenesis

Date/Time: April 18, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/5493

In vivo Efficacy of an Anti-Human IL11RA Antibody in B-hIL11RA Mice With APAP-Induced Liver Damage

Poster Number: 3993

Session: Oncogenes and Tumor Suppressor Genes as Targets for Therapy 3

Date/Time: April 18, 2023, 9:00 AM – 12:30 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/8652

Novel Humanized CD36 Mouse Model for Therapeutic Studies

Poster Number: 5196

Session: Novel Preclinical Models for Cancer Immunotherapy

Date/Time: April 18, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6977

Off-the-Shelf Mouse Models - Immunodeficient Mice

Development of Immunodeficient Mice Expressing Human IL3, GM-CSF, CSF1 and THPO for Improved Human Myeloid and Lymphoid Cell Reconstitution

Poster Number: 5208

Session: Novel Preclinical Models for Cancer Immunotherapy

Date/Time: April 18, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6987

Development of MHC I/II Knock-Out Immunodeficient Mouse Strains for Alleviating GvHD Induced by Human PBMC Reconstitution

Poster Number: 5207

Session: Novel Preclinical Models for Cancer Immunotherapy

Date/Time: April 18, 2023, 1:30 PM – 5:00 PM

Abstract: https://www.abstractsonline.com/pp8/#!/10828/presentation/6982

About AACR Annual Meeting

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

About Biocytogen

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab^TM/RenLite^®/RenNano^TM mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMice^TM HiTS Platform). As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice^TMlicensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.

Biocytogen’s Contacts

Antibody assets and platforms: BD-Licensing@biocytogen.com

BioMice models: info@bbctg.com.cn

Media: pr@bbctg.com.cn